Cancer Trials Should Show Minimum 20% Overall Survival Benefit, ASCO Suggests
This article was originally published in The Pink Sheet Daily
American Society of Clinical Oncology draft recommendations provide benchmarks for Phase III oncology drug trials, including a minimum 20% improvement in overall survival, with a higher bar for certain diseases.
You may also be interested in...
ASCO reflected diverse lay of the land for the challenging development space, with new drugs coming from Merrimack, Halozyme, Threshold and a range of immunotherapy combinations. Meanwhile, Celgene’s Abraxane appears to be on blockbuster track.
A study of oncology approvals since 2002 concludes that only 42% represented a “clinically meaningful improvement” in therapy. High prices encourage a “me-too” mentality that directs R&D investment to marginal indications, the authors assert.
Using anonymous examples at the recent AACR meeting, FDA’s Tatiana Prowell highlights mistakes made and lessons learned in oncology drug reviews.